AIM ImmunoTech Completes Phase 2 Enrollment; Coiled Names Craig Tooman to Board
AIM•AIM ImmunoTech completed Phase 2 DURIPANC enrollment ahead of schedule, dosing the final patient with Ampligen plus durvalumab and reporting positive interim safety and efficacy observations, with topline results expected Q1 2027. AIM-listed Coiled Therapeutics appointed biotech veteran Craig Tooman to its board effective June 25 to bolster oncology governance.
1. AIM ImmunoTech Program Milestones
Over the past months, AIM ImmunoTech accelerated its pancreatic cancer program by completing Phase 2 DURIPANC enrollment ahead of schedule, dosing the final patient in combination with AstraZeneca’s durvalumab and reporting positive interim safety and efficacy data. The company has maintained orphan drug designation in major markets, expanded its IP portfolio, regained compliance with NYSE American listing standards and strengthened its balance sheet to support strategic clinical priorities. Upcoming catalysts include initiation of primary endpoint analysis in December 2026 with topline results in Q1 2027, PFS and OS assessments in June 2027, further biomarker analyses, regulatory interactions and Phase 3 planning activities.
2. Coiled Therapeutics Board Appointment
Coiled Therapeutics, listed on the AIM market, appointed Craig Tooman as an independent non-executive director effective June 25. Tooman brings extensive leadership experience from his tenure as President, CEO and board director at Silence Therapeutics, an siRNA specialist, positioning Coiled to benefit from his expertise in advancing clinical-stage oncology and nucleic acid therapies.
